Renovaro BioSciences Welcomes GEDiCube Announcement of New Joint Effort
30 Août 2023 - 3:15PM
(NASDAQ: RENB). Renovaro BioSciences congratulates GEDiCube on
their joint effort to work to accelerate early diagnosis of cancer
in clinical trials.
For more information: GEDiCube Press Release
FORWARD-LOOKING STATEMENT
Statements in this press release that are not
strictly historical in nature are forward-looking statements. These
statements are only predictions based on current information and
expectations and involve a number of risks and uncertainties,
including but not limited to the success or efficacy of our
pipeline. All statements other than historical facts are
forward-looking statements, which can be identified by the use of
forward-looking terminology such as “believes,” “plans,” “expects,”
“aims,” “intends,” “potential,” or similar expressions. All
forward-looking statements are based on assumptions or judgments
about future events and economic conditions that may or may not be
correct or necessarily take place and that are by their nature,
subject to significant risks, uncertainties, and contingencies.
These forward-looking statements include but are not limited to,
statements regarding the Renovaro-GEDi Cube transaction and
Renovaro’s plans and expectations with respect to the potential
transaction. Actual events or results may differ materially from
those projected in any of such statements due to various
uncertainties, including as set forth in Renovaro BioSciences Inc.
(NASDAQ: RENB) most recent Annual Report on Form 10-K filed with
the SEC as well as whether Renovaro and GEDi Cube will enter into
an agreement as to the definitive terms of the transaction; a
condition to consummating the transaction may not be satisfied;
Renovaro may be unable to obtain approval to list on the Nasdaq
Capital Market the shares of Renovaro common stock expected to be
issued pursuant to the transaction; the closing of the transaction
might be delayed or not occur at all. Readers are cautioned not to
place undue reliance on these forward-looking statements, which
speak only as of the date hereof. All forward-looking statements
are qualified in their entirety by this cautionary statement, and
Renovaro Biosciences, Inc. undertakes no obligation to revise or
update this shareholder letter to reflect events or circumstances
after the date hereof.
Investor Relations Contact: ir@renovarobio.com
Renovaro (NASDAQ:RENB)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
Renovaro (NASDAQ:RENB)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024